Epidermal Growth Factor Receptor & ErbII (EGFR/ErbB-2)

Product #


Biochem/physiol Actions

Add to Cart

SML1400 AEE788 ≥98% (HPLC) AEE788 is an orally available and potent dual family of human EGFR and VEGFR receptor tyrosine kinase inhibitor that exhibits potent antitumor and antiangiogenic activity.
SML1494 BMS-599626 ≥98% (HPLC) BMS-599626 is a potent inhbitor of human epidermal growth factor receptors 1 and 2 (HER1 and HER2, IC50 = 20 and 30 nM, respectively). BMS599626 inhibits proliferation of several HER-expressing cancer cell lines, including HER2-overexpressing breast cancer lines, but does not affect the proliferation rate of HER-negative cancer cell lines.
C7249 CI-1033 ≥98% (HPLC) CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.
PZ0335 CP724714 ≥98% (HPLC) CP724714 is a potent and selective inhibitor of HER2/ErbB2 with an IC50 value of 10 nM. CP724714 is >640-fold selectivity against EGFR, and >1000-fold selective against InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met, JNK-2, JNK-3, ZAP-70, CDK-2 and CDK-5 in in vitro kinase assays. CP724714 had antiproliferative effects in a panel of human breast cancer cell lines.
SML1171 GSA-10 ≥98% (HPLC) GSA-10 is a novel, potent activator of the smoothened receptor (Smo). GSA-10 binds to Smo at a unique site compared to agonists such as SAG and purmorphamine, and is not affected by the Smo antagonist cyclopamine. GSA-10 promotes the differentiation of mesenchymal pluripotent C3H10T1/2 cells into osteoblasts.
G0668 GW2974 ≥98% (HPLC), solid Potent and selective dual inhibitor of EGFR (IC50 = 0.016 mM) and ErbB-2 receptor tyrosine kinase.
G3545 GW583340 dihydrochloride ≥97% (HPLC), solid Potent dual ErbB-2/EGFR tyrosine kinase inhibitor. IC50= 0.01 and 0.014 μM for EGFR and ErbB-2. Orally active.
PZ0302 PF-06747775 ≥98% (HPLC) PF-06747775 is an orally available, potent and selective inhibitor of the epidermal growth factor receptor) mutant form T790M (EGFR T790M inhibitor). PF-06747775 exhibits minimal activity against wild type EGFR.
SML1168 WZ4002 ≥98% (HPLC) WZ4002 is an irreversible inhibitor of the gatekeeper EGFR-T790M mutation that binds to the active conformation of the EGFR kinase forming a covalent bond with Cys 797.
WZ4002 is effective in the treatment of lung adenocarcinomas due to EGFR (epidermal growth factor receptor) mutations.